delta 4-ethylestrenol in recurrent deep venous thrombosis.
In a study of 21 patients with recurrent venous thrombosis and/or thrombophlebitis, fibrinolytic activity measured after venous occlusion was significantly improved after treatment with 6 mg delta 4-ethylestrenol (Orgabolin) daily. Seven of the 21 patients had abnormally low vessel wall plasminogen activator content, which normalised during treatment. No tendency to develop resistance to the drug was observed during treatment for periods up to 56 months. This improvement was shown to be combined with a significant lower (p less than 0.001) incidence of thrombosis.
D000328:Adult; D000368:Aged; D005032:Ethylestrenol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000032:analysis; D013924:Thrombophlebitis / Q000188:drug therapy*
D005032:Ethylestrenol; D010960:Plasminogen Activators